3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
60
Neoplasm Metastasis
6
Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Ovarian Neoplasms
2
Neuroblastoma
2
Neoplasms by Site
2
Melanoma
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Glioblastoma
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Meningioma
1
Medulloblastoma
1
Interventions
Anastrozole
5
palbociclib
4
abemaciclib
3
Trastuzumab
3
Fulvestrant
3
ribociclib
2
pertuzumab
2
exemestane
2
Tamoxifen
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
trastuzumab deruxtecan
1
taxane
1
elacestrant
1
dalpiciclib
1
STX-478
1
RAD1901
1
Metformin
1
Leflunomide
1
Imlunestrant
1
Genotype
1
Body Height
1
Blood Specimen Collection
1
Blood Pressure
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Diseases
×
ribociclib
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled